The news: AstraZeneca is rolling out the first flu vaccine for at-home use, a nasal spray called FluMist Home. Our take: AstraZeneca’s at-home vaccine option offers an appealing new convenience but still faces vaccine hesitancy and change skeptics. While the marketing is just rolling out, social media parent influencer voices and partnering with trusted physicians will be important to build trust.

FDA approves AstraZeneca’s flu vaccine for at-home administration: But we’re not certain FluMist’s convenient nasal spray format gives it enough of an edge over traditional vaccines to drive adoption among vaccine hesitant Americans.